Biogena Group Invest Sets Sights on €500 Million Revenue with Accelerated Restructuring
Published on 07/14/2026 at 05:13 | Redaktion boerse-global.de
Biogena Group Invest is charting an ambitious course that could transform its profile at the Vienna Stock Exchange. CEO Albert Schmidbauer laid out plans on Monday to elevate the company from its current listing segment to the more tightly regulated Standard Market, a shift that would align with its expanding scale. The move dovetails with a broader overhaul designed to make the stock more accessible to institutional investors.
The group’s operating momentum has picked up sharply. In its most recent fiscal year, Biogena exceeded €100 million in revenue for the first time, representing a 44% surge. Management now expects that figure to reach €150-155 million in the current period ending 30 September, and has set a long-term goal of roughly €500 million by 2030. The biggest growth lever, according to Schmidbauer, is the German market, where Biogena currently holds a mere 0.7% share — a figure the company aims to push toward 3%.
Financing this expansion requires fresh capital, and Biogena has moved on two fronts. The operating subsidiary placed a €20 million bond that was oversubscribed, closing early due to strong demand. Meanwhile, the parent company, Biogena Good Vibes AG, is conducting an off-exchange capital increase of €25 million, priced at €4.803 per share, with subscriptions closing in July. Proceeds from both instruments will fund the build-out of production facilities in Koppl near Salzburg and help lift the free float from negligible levels to between 3.5% and 5.5%. An additional 3.5% could be unlocked later when the parent merges into the already-listed Biogena Group Invest, creating a simpler structure more palatable to institutional buyers.
Should investors sell immediately? Or is it worth buying Biogena Group Invest?
The market has responded enthusiastically to the roadmap. The stock closed Monday at €4.70, matching its 52-week high from 22 June, and has surged nearly 40% in the past 30 days alone. Year-to-date the advance stands at 56.67%. Despite the rally, the relative-strength index sits at 64.6 — still below the overbought threshold of 70. The stock’s volatility, however, remains elevated at 83.3%, a reminder of the speculative nature surrounding the group’s restructuring. With a market capitalisation of just €17.72 million, Biogena Group Invest is a small-cap name prone to sharp moves on corporate news.
The coming weeks are pivotal. After the subscription period ends in July, Biogena intends to list the entire group on the Vienna Stock Exchange in August. Only then will management disclose the exchange ratio and timeline for the proposed merger of the two listed entities. The half-year results, due around the same time, will be closely watched for margin trends as the company pursues aggressive expansion in Germany.
Ad
Biogena Group Invest Stock: New Analysis - 14 July
Fresh Biogena Group Invest information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
